Teva’s Generic Drug Labeling Fight Turned Away by Supreme Court

Teva Pharmaceuticals failed to persuade the US Supreme Court to review a generic drug labeling decision that critics say threatens how lower-cost medications come to market.

The high court Monday declined to review a case over a common practice known as “skinny labeling,” which involves leaving a name-brand drug’s patented uses off of a generic label to avoid infringement liability. Teva argued a lower court’s decisions, if allowed to stand, would wreak havoc on competition.

Justice Brett Kavanaugh would have granted the petition for review, according to the Supreme Court order.

The US Court of Appeals for the Federal Circuit ...